Easier to predict the future for leukemia patients

02-26-2008

Researchers at Umeå University in Sweden are showing that the length of telomeres in leukemia cells is tied to specific genetic aberrations and is an independent diagnostic marker that can tell us something about the future prospects for leukemia patients. A research team directed by Professor Göran Roos at the Department of Medical Bioscience, Pathology, is behind the study, which is now being published in the journal Blood.

The study, carried out in collaboration with colleagues at Ulm University, Germany, and at Uppsala University, Sweden, shows that the length of telomeres in chronic lymphatic leukemia (CLL) cells is tied to specific genetic aberrations of known prognostic significance. Cases with no chromosome 17p or 11q evinced short telomeres, while cases with no 13q had significantly longer telomeres. Other known prognostic factors, such as the number of mutations in immunoglobulin genes, expression of the proteins ZAP70 and CD38, and clinical stage, were all significantly associated with telomere length as well. It was interesting that telomere length proved to be a prognostic marker that is independent of all of these factors. In other words, it can tell us more about the future prospects of leukemia patients than previously known markers are able to.

The tips of chromosomes, telomeres, are important for the genetic stability of our cells. In normal cells, telomeres are shortened each time the cell divides, whereas cancer cells usually have stable telomere length. This stability helps lend cancer cells 'eternal' life. The telomere length of a cell is determined by a balance between positive and negative factors, many of which are unknown. Short telomeres have been shown to be tied to unstable genes. This research team has previously demonstrated that patients with CLL where the leukemia cells evince short telomeres (reduced median length) have a significantly poorer prognosis than patients with long telomeres (Grabowski et al. 2005; Blood, 105(12):4807-12).

For more information, please contact Professor Göran Roos, Department of Medical Bioscience, Section for Pathology, phone: +46 (0)90-785 18 01, e-mail goran.roos@medbio.umu.s.

A high-resolution picture of Göran Roos can be downloaded from
http://www.umu.se/medfak/aktuellt/bilder/index.html

Reference: Roos G, Kröber A, Grabowski P, Kienle D, Bühler A, Döhner H, Rosenquist R, Stilgenbauer S. Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia. Blood. 2008 Feb 15;111(4):2246-52. http://bloodjournal.hematologylibrary.org/cgi/content/full/111/4/2246

Commentary: Lin TS. Do short telomeres shorten CLL survival? Blood, 15 February 2008, Vol. 111, No. 4, pp. 1755.
Weitere Informationen: http://bloodjournal.hematologylibrary.org/cgi/content/full/111/4/2246

Source: The Swedish Research Council



Related Diseases: Chronic Lymphocytic Leukemia (CLL)
Related Keywords: Zap-70, CD38
Related Glossary Terms: CLL
 
RECENT NEWS
 
Acute Lymphocytic Leukemia (ALL)
Improved Survival in Pediatric Leukemia Following Unrelated Bone Marrow but not Peripheral Blood Stem Cell Transplantation
Hana Biosciences' rALLy Clinical Trial of Marqibo Meets Response Criteria to Advance to Full Enrollment
Rituxan® Maintenance in Follicular Lymphoma Deemed Cost-effective
Injection of Umbilical Cord Stem Cells into Bone Appears Promising for Leukemia
Protein key to control, growth of blood cells
Acute Myeloid Leukemia (AML)
Improved Survival in Pediatric Leukemia Following Unrelated Bone Marrow but not Peripheral Blood Stem Cell Transplantation
New leukemia signal could point way to better treatment, Stanford researchers find
Cyclacel expands Phase 2 sapacitabine trial in elderly AML to include patients with MDS
FDA Approves Vidaza Label Expansion
Rituxan® Maintenance in Follicular Lymphoma Deemed Cost-effective
Amyloidosis
High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis
STEM CELL TRANSPLANTATION PROCEDURE RESULTS IN LONG-TERM SURVIVAL FOR AMYLOIDOSIS PATIENTS
Neurochem receives approvable letter for eprodisate (KIACTA) for treatment of AA amyloidosis
Neurochem, Inc. (NRMX) Receives Approvable Letter for Eprodisate (KIACTA(TM)) for Treatment of AA Amyloidosis; FDA Asks for More Data
Aplastic Anemia
Blood Stem Cells Originate in the Placenta
Stem Cells from a Person's Own Umbilical Cord Effective Treatment For Life-Threatening Blood Disease, Study Data Show
Alexion's Soliris Granted Marketing Approval in Europe for Treatment of All Patients With PNH
Soliris(TM) Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes
Decision Fails Patients with Transfusion-Dependent Anemia
Chronic Lymphocytic Leukemia (CLL)
Improved Survival in Pediatric Leukemia Following Unrelated Bone Marrow but not Peripheral Blood Stem Cell Transplantation
Injection of Umbilical Cord Stem Cells into Bone Appears Promising for Leukemia
Protein key to control, growth of blood cells
GlaxoSmithKline And Genmab Announce Positive Top-line Results In Ofatumumab Chronic Lymphocytic Leukaemia Pivotal Study
Sparing leukemia patients from unnecessary chemo
Chronic Myeloid Leukemia (CML)
Improved Survival in Pediatric Leukemia Following Unrelated Bone Marrow but not Peripheral Blood Stem Cell Transplantation
Promyelocytic Blast Crisis of Chronic Myeloid Leukemia during Imatinib Treatment
Injection of Umbilical Cord Stem Cells into Bone Appears Promising for Leukemia
Protein key to control, growth of blood cells
Targeted therapies for CML: practical considerations and comparisons
Hodgkin Lymphoma
Queen's University Using Xceed Molecular's Ziplex in Follicular Lymphoma Study
Lymphoma 101: Everything you need to know
September Is National Leukemia and Lymphoma Awareness Month
Nerve cancer mutations found
Autologous Stem Cell Transplantation Effective for Relapsed or Refractory Hodgkin’s Lymphoma
Multiple Myeloma
Thalomid® in Induction Improves Progression-free Survival in Elderly with Myeloma
The IMF says journal editorial documents dramatic increase in survival since the 1980s
FDA Approves Vidaza Label Expansion
Bortezomib (Velcade) in Combo Scores For Initial Myeloma Treatment
B-MS boosts biologics pipeline with PDL BioPharma deal
Myelodysplastic Syndrome (MDS)
Cyclacel expands Phase 2 sapacitabine trial in elderly AML to include patients with MDS
FDA Approves Vidaza Label Expansion
Xanthus Presents Updated Xanafide Phase 2 Data Showing Durable Complete Remissions in Secondary AML
Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine (VNP40101M) in Combination with Cytarabine
ZIOPHARM Presents Positive Data From Phase II Study Of Darinaparsin In Advanced Hematological Malignancies At AACR 2008 Annual Meeting
Non-Hodgkin Lymphoma (NHL)
Queen's University Using Xceed Molecular's Ziplex in Follicular Lymphoma Study
Lymphoma 101: Everything you need to know
Dose Intensity Associated with Survival in Non-Hodgkin’s Lymphoma
September Is National Leukemia and Lymphoma Awareness Month
Dose Intensity Associated with Survival in Non-Hodgkin’s Lymphoma
Testicular Cancer
Single Dose of Carboplatin as Effective as Radiation Therapy for Testicular Cancer
Single Dose of Chemotherapy as Effective as Weeks of Radiation Therapy for Testicular Cancer
Drug avoids radiation for early testicular cancer
Polymorphism Reduces Benefit of Bleomycin in Testicular Cancer
Increased Life Expectancy Seen For Patients With Advanced Colorectal, Ovarian and Testicular Cancer